Beta-adrenergic receptor agonists and cyclic nucleotide phosphodiesterase inhibitors: Shifting the focus from inotropy to cyclic adenosine monophosphate

Journal of the American College of Cardiology

Volumn 34, Issue 2, 1999, Pages 318-324

  Movsesian, Matthew A ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE INHIBITOR; UNCLASSIFIED DRUG;

CALCIUM TRANSPORT; HEART CONTRACTION; HEART FAILURE; INOTROPISM; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 0032698819     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(99)00220-X     Document Type: Article

References (60)

1. Movsesian M.A. cAMP-mediated signal transduction in heart failure: molecular pathophysiology and therapeutic implications. J Invest Med. 45:1997;432-440.
2. 1-receptor down-regulation in heart failure. Circ Res. 59:1986;297-309.
3. Feldman A.M., Cates A.E., Veazey W.B., et al. Increase in the 40,000-mol wt pertussis toxin substrate (G protein) in the failing human heart. J Clin Invest. 82:1988;189-197.
4. 1-adrenergic receptors in the failing human heart. Circulation. 87:1993;454-463.
5. Niroomand F, Lutz S, Mura R, Baltus D. Increased activity of membrane-associated nucleoside diphosphate kinase leads to inhibition of adenylyl cyclase in membranes from failing human myocardium. Circulation 1997;96:I-495-6.
6. Sculptoreanu A., Rotman E., Takahashi M., et al. Voltage-dependent potentiation of the activity of cardiac L-type calcium channel alpha 1 subunits due to phosphorylation by cAMP-dependent protein kinase. Proc Natl Acad Sci USA. 90:1993;10135-10139.
7. Witcher D.R., Kovacs R.J., Schulman H., et al. Unique phosphorylation site on the cardiac ryanodine receptor regulates calcium channel activity. J Biol Chem. 266:1991;11144-11152.
8. 2+ pump of the sarcoplasmic reticulum. Nature. 342:1989;90-92.
9. Tobacman L.S. Thin filament-mediated regulation of cardiac contraction. Ann Rev Physiol. 58:1996;447-481.
10. Hagiwara M., Brindle P., Harootunian A., et al. Coupling of hormonal stimulation and transcription via the cyclic AMP-responsive factor CREB is rate limited by nuclear entry of protein kinase A. Mol Cell Biol. 13:1993;4852-4859.
11. Fentzke R.C., Korcarz C.E., Lang R.M., et al. Dilated cardiomyopathy in transgenic mice expressing a dominant-negative CREB transcription factor in the heart. J Clin Invest. 101:1998;2415-2426.
12. Goldberg L.I., Hsieh Y.-Y., Resnekov L. Newer catecholamines for treatment of heart failure and shock: an update on dopamine and dobutamine. Prog Cardiovasc Dis. 19:1977;327-340.
13. Dies F., Krell M.J., Whitlow P., et al. Intermittent dobutamine in ambulatory patients with chronic cardiac failure. (abstr) Circulation. 76:1986;II-38.
14. Xamoterol in severe heart failure. Lancet. 336:1990;1-6.
15. Komas N., Movsesian M., Kedev S., et al. cGMP-inhibited cyclic nucleotide phosphodiesterases. Schudt C., Dent G., Rabe K.F. Phosphodiesterase Inhibitors. 1996;89-109 Academic Press, San Diego (CA).
16. Movsesian M.A., Smith C.J., Krall J., et al. Sarcoplasmic reticulum-associated cyclic adenosine 5′-monophosphate phosphodiesterase activity in normal and failing human hearts. J Clin Invest. 88:1991;15-19.
17. Benotti J.R., Grossman W., Braunwald E., et al. Hemodynamic assessment of amrinone. N Engl J Med. 299:1978;1373-1377.
18. Baim D.S., McDowell A.V., Cherniles J., et al. Evaluation of a new bipyridine inotropic agent - milrinone - in patients with severe congestive heart failure. N Engl J Med. 309:1983;748-756.
19. Sinoway L.S., Maskin C.S., Chadwick B., et al. Long-term therapy with a new cardiotonic agent, WIN 47203: drug-dependent improvement in cardiac performance and progression of the underlying disease. J Am Coll Cardiol. 2:1983;327-331.
20. Uretsky B.F., Generalovich T., Reddy P.S., et al. The acute hemodynamic effects of a new agent, MDL 17,043, in the treatment of congestive heart failure. Circulation. 67:1983;823-828.
21. Jaski B.E., Fifer M.A., Wright R.F., et al. Positive inotropic and vasodilator actions of milrinone in patients with severe congestive heart failure. J Clin Invest. 75:1985;643-649.
22. DiBianco R., Shabetai R., Silverman B.D., et al. Oral amrinone for the treatment of chronic congestive heart failure: results of a multicenter randomized double-blind and placebo-controlled withdrawal study. J Am Coll Cardiol. 4:1984;855-866.
23. Massie B., Bourassa M., DiBianco R., et al. Long-term oral administration of amrinone for congestive heart failure: lack of efficacy in a multicenter controlled trial. Circulation. 71:1985;963-971.
24. DiBianco R., Shabetai R., Kostuk W., et al. A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure. N Engl J Med. 320:1989;677-683.
25. Uretsky B.F., Jessup M., Konstam M.A., et al. Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure. Lack of benefit compared with placebo. Circulation. 82:1990;774-780.
26. Packer M., Carver J.R., Rodeheffer R.J., et al. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med. 325:1991;1428-1475.
27. Nony P., Boissel J.-P., Lièvre M., et al. Evaluation of the effect of phosphodiesterase inhibitors on mortality in chronic heart failure patients. Eur J Clin Pharmacol. 46:1994;191-196.
28. Waagstein F., Bristow M.R., Swedberg K., et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet. 342:1993;1441-1446.
29. Packer M., Bristow M.R., Cohn J.N., et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 334:1996;1349-1355.
30. Gilbert E.M., Abraham W.T., Olsen S., et al. Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation. 94:1996;2817-2825.
31. Exton J.H. Mechanisms of hormonal regulation of hepatic glucose metabolism. Diabetes Metab Rev. 3:1987;163-183.
32. Benovic J.L., Pike L.J., Cerione R.A., et al. Phosphorylation of the mammalian β-adrenergic receptor by cyclic AMP-dependent protein kinase. Regulation of the rate of receptor phosphorylation and dephosphorylation by agonist occupancy and effects on coupling of the receptor to the stimulatory guanine nucleotide regulatory protein. J Biol Chem. 260:1985;7094-7101.
33. Erlichman J., Rosenfeld R., Rosen O.M. Phosphorylation of a cyclic adenosine 3′:5′-monophosphate-dependent protein kinase from bovine cardiac muscle. J Biol Chem. 249:1974;5000-5003.
34. Böhm M., Diet F., Feiler G., et al. Subsensitivity of the failing human heart to isoprenaline and milrinone is related to β-adrenoceptor downregulation. J Cardiovasc Pharmacol. 12:1988;726-732.
35. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 336:1997;525-533.
36. 1. J Biol Chem. 255:1980;5113-5119.
37. Buxton I.L., Brunton L.L. Compartments of cyclic AMP and protein kinase in mammalian cardiomyocytes. J Biol Chem. 258:1983;10233-10239.
38. 2+ dynamics, contractility, or phospholamban phosphorylation. J Biol Chem. 269:1994;19151-19156.
39. 2-adrenoceptor agonists in guinea pig hearts. J Cardiovasc Pharmacol. 26:1995;893-898.
40. 2-adrenoceptor to a pertussis toxin-sensitive G protein in cardiac myocytes. Mol Pharmacol. 47:1995;322-329.
41. 2+ transients. Circulation. 69:1991;1369-1379.
42. 2+ current in single rat ventricular cells. Circ Res. 73:1993;286-300.
43. 2-adrenergic stimulation. Circulation. 92:1995;1612-1618.
44. 2-adrenergic modulation of cardiac excitation-contraction coupling. Am J Physiol. 273:1997;H1611-H1618.
45. Böhm M., Reiger B., Schwinger R.H.G., Erdmann E. cAMP concentrations, cAMP dependent protein kinase activity, and phospholamban in non-failing and failing myocardium. Cardiovasc Res. 28:1994;1713-1719.
46. Shakar S.F., Abraham W.T., Gilbert E.M., et al. Combined oral positive inotropic and beta-blocker therapy for treatment of refractory class IV heart failure. J Am Coll Cardiol. 31:1998;1336-1340.
47. m, cGMP-inhibited cAMP phosphodiesterase in mammalian myocardium. Biochem Biophys Res Commun. 190:1993;516-521.
48. Ogreid D., Ekanger R., Suva R.H., et al. Comparison of the two classes of binding sites (A and B) of type I and type II cyclic-AMP-dependent protein kinases by using cyclic nucleotide analogs. Eur J Biochem. 181:1989;19-31.
49. Dostmann W.R.G., Taylor S.S., Genieser H.-G., et al. Probing the cyclic nucleotide binding sites of cAMP-dependent protein kinases I and II with analogs of adenosine 3′,5′-cyclic phosphorothioates. J Biol Chem. 265:1990;10484-10491.
50. Gjertsen B.T., Mellgren G., Otten A., et al. Novel (Rp)-cAMPS analogs as tools for inhibition of cAMP-kinase in cell culture. J Biol Chem. 270:1995;20599-20607.
51. Skålhegg B.S., Landmark B.F., Døskeland S.O., et al. Cyclic AMP-dependent protein kinase type I mediates the inhibitory effects of 3′,5′-cyclic adenosine monophosphate on cell replication in human T lymphocytes. J Biol Chem. 267:1992;15707-15714.
52. Laxminarayana D., Berrada A., Kammer G.M. Early events of human T lymphocyte activation are associated with type I protein kinase A activity. J Clin Invest. 92:1993;2207-2214.
53. Beebe S.J., Holloway R., Rannels S.R., Corbin J.D. Two classes of cAMP analogs which are selective for the two different cAMP-binding sites of type II protein kinase demonstrate synergism when added together to intact lymphocytes. J Biol Chem. 259:1984;3539-3547.
54. Corbin J.D., Sugden P.H., Lincoln T.M., Keely S.L. Compartmentalization of adenosine 3′:5′-monophosphate and adenosine 3′:5′-monophosphate-dependent protein kinase in heart tissue. J Biol Chem. 252:1977;3854-3861.
55. Mumby M.C., Walter G. Protein serine/threonine phosphatases: structure, regulation and functions in cell growth. Physiol Rev. 73:1993;673-699.
56. Wera S., Hemmings B.A. Serine/threonine protein phosphatases. Biochem J. 311:1995;17-29.
57. McCright B., Virshup D.M. Identification of a new family of protein phosphatase 2A regulatory subunits. J Biol Chem. 270:1995;26123-26128.
58. Linck B., Boknik P., Knapp J., et al. Effects of cantharidin on force of contraction and phosphatase activity in nonfailing and failing human hearts. Br J Pharmacol. 119:1996;545-550.
59. Molkentin J.D., Lu J.R., Antos C.L., et al. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell. 93:1998;215-228.
60. Sussman M.A., Lim H.W., Gude N., et al. Prevention of cardiac hypertrophy in mice by calcineurin inhibition. Science. 281:1998;1690-1693.